BNP Paribas Financial Markets
SLN icon

BNP Paribas Financial Markets’s Silence Therapeutics SLN Stock Holding History

BNP Paribas Financial Markets’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Buy
158,950
+11,282
+8% +$79.4K ﹤0.01% 2911
2026
Q1 		$778K Buy
147,668
+135,641
+1,128% +$747K ﹤0.01% 3311
2025
Q4 		$73.1K Buy
12,027
+11,427
+1,905% +$73.2K ﹤0.01% 4514
2025
Q3 		$3.11K Sell
600
-100
-14% -$555 ﹤0.01% 5135
2025
Q2 		$4.06K Sell
700
-4,088
-85% -$17.5K ﹤0.01% 4978
2025
Q1 		$13.5K Buy
4,788
+3,004
+168% +$14.7K ﹤0.01% 4644
2024
Q4 		$12.3K Buy
+1,784
New +$23K ﹤0.01% 4815

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BNP Paribas Financial Markets's SLN Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Silence Therapeutics (SLN) stake by 7.6% in Q2 2026, buying an estimated $79.4K and bringing the position to 158,950 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

BNP Paribas Financial Markets first reported a position in SLN in Q4 2024 and has held it in 7 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • BNP Paribas Financial Markets held 158,950 shares of Silence Therapeutics worth $1.75M as of Q2 2026.
  • BNP Paribas Financial Markets bought 11,282 Silence Therapeutics shares in Q2 2026, an estimated $79.4K.
  • Silence Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2911 holding.
  • BNP Paribas Financial Markets first reported a position in Silence Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.